ストックスクリーナーアプリを入手
13.52
2.17%
-0.2997
アフターアワーズ：
13.52
-0.0039
-0.03%
前日終値:
$13.82
開ける：
$13.5239
24時間の取引高:
126
Relative Volume:
2.41
時価総額：
$3.02M
収益：
$2.76M
当期純損益:
$-112.96M
株価収益率:
-0.3853
EPS:
-35.1
ネットキャッシュフロー:
$-96.46M
1週間 パフォーマンス:
-19.62%
1か月 パフォーマンス:
-19.62%
6か月 パフォーマンス:
-19.62%
1年 パフォーマンス:
-19.62%
1日の値動き範囲:
$13.52
$13.52
1週間の範囲:
$13.52
$14.30
52週間の値動き範囲:
$13.52
$14.30
Homology Medicines Inc Stock (FIXX) Company Profile
Compare FIXX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FIXX
Homology Medicines Inc
|
13.52 | 3.02M | 2.76M | -112.96M | -96.46M | -35.10 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Homology Medicines Inc Stock (FIXX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-25 | 開始されました | H.C. Wainwright | Buy |
| 2025-02-11 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-02-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-12-11 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | Raymond James | Strong Buy |
| 2024-09-11 | 開始されました | Wells Fargo | Overweight |
| 2024-06-17 | 開始されました | Guggenheim | Buy |
| 2024-05-21 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Piper Sandler | Overweight |
| 2023-07-28 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-02-22 | 繰り返されました | BTIG Research | Neutral |
| 2022-02-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-02-22 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2020-12-14 | 再開されました | H.C. Wainwright | Buy |
| 2020-08-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-03-16 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-24 | 開始されました | Chardan Capital Markets | Buy |
| 2019-11-01 | 開始されました | Oppenheimer | Perform |
| 2019-09-10 | 開始されました | Robert W. Baird | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-20 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-07 | 開始されました | Canaccord Genuity | Buy |
| 2018-09-07 | 開始されました | B. Riley FBR | Neutral |
すべてを表示
Homology Medicines Inc (FIXX) 最新ニュース
Antineutrophil Cytoplasmic Antibody (ANCA) Associated - openPR.com
Overview of Segmentation, Market Dynamics, and Competitive Landscape in the Mucolipidosis II Market - openPR.com
Emerging Sub-Segments Transforming the Lysosomal Enzyme Market Landscape - openPR.com
Form S-3 Q32 Bio Inc For: 17 July By Investing.com - Investing.com Canada
Q32 Bio (Nasdaq: QTTB) files to register 6.9M shares for resale - Stock Titan
Vitiligo Therapeutics Market Projected to Reach USD 2.28 Billion by 2032 - Yahoo Finance
Form 424B5 Q32 Bio Inc For: 15 July By Investing.com - Investing.com Canada
Form 424B5 Q32 Bio Inc For: 13 July By Investing.com - Investing.com Canada
Nucleic Acid Based Gene Therapy Market Report Evaluates Growth Drivers, Challenges And Market Dynamics - openPR.com
Q32 Bio (NASDAQ: QTTB) files $300M shelf; May 26 $55M placement noted - Stock Titan
Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary - Weekly Voice
Phenylketonuria Market Size, Share, Growth, Analysis, Report, 2034 - Straits Research
QTTB - Finviz
This Q32 Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Sahm
Obesity Treatment Development: Challenges and Future Focus - Technology Networks
Mucolipidosis II Market Analysis: Major Segments, Strategic Developments, and Leading Companies - openPR.com
ATLAS VENTURE ASSOCIATES X L P Net WorthInsider Trades and Bio as of Apr 23, 2026 - Benzinga
Leading Companies Fueling Innovation and Growth in the Mucopolysaccharidosis Treatment Market - openPR.com
DEERFIELD PARTNERS L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Krabbe Disease Treatment Market Overview, Emerging Trends, and Key Player Analysis - openPR.com
Analysis of Key Market Segments Influencing the CRISPR Gene Editing Market - openPR.com
Deerfield Mgmt HIF L P Net WorthInsider Trades and Bio as of Apr 22, 2026 - Benzinga
Growth Patterns, Segment Analysis, and Competitive Approaches - openPR.com
Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026 - EIN News
Analysis of Market Segments and Major Growth Areas in the Nucleic Acid Based Gene Therapy Market - openPR.com
Biotech Expansion Accelerating Viral Vector Manufacturing Market Insights 2026–2035 - Weekly Voice
Q32 Bio Hits New HighRegrowth Signals? - RTTNews
Q32 Bio (QTTB) One Off Driven Q4 Profit Challenges Earnings Decline Narrative - Sahm
Q32 Bio Inc. 2025 Annual Report: Business Overview, Pipeline, Risks, and Intellectual Property Strategies - Minichart
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight - Sahm
CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO - TipRanks
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation - Fox21Online
Brain cancer drug developer hires CFO, CTO and CBO in strategic reset - Stock Titan
$191.2 Million Achromatopsia Market Outlook, 2026-2032, Featuring Adverum Biotechnologies, Homology Medicines, Mattel, REGENXBIO, Sanofi and More - Yahoo Finance
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer - BioSpace
Editas Medicine nominates lead in vivo development candidate - BioWorld News
AAV for the Hereditary Retinal Diseases Clinical Trial - GlobeNewswire
OXB completes acquisition of remaining stake in US subsidiary - GlobeNewswire
Mucopolysaccharodisis Treatment Market Size & Share, 2033 - Market Data Forecast
Mammoth nominates development candidate for FCS and severe hypertriglyceridemia - BioWorld MedTech
Qatar’s $320bn wealth fund seeks to catch up on tech - businessreport.co.za
Stoke Therapeutics Announces CEO Transition - Business Wire
Q32 Bio Inc. (QTTB) reports earnings - qz.com
Versatope Adds New Board Members - PR Newswire
QTTB stock touches 52-week low at $2.59 amid market challenges - Investing.com
Homology Medicines (NASDAQ: FIXX)Share Price - intelligentinvestor.com.au
100 cell and gene therapy leaders to watch in 2025 - drugdiscoverytrends.com
Growth Trends in the CRISPR and Cas Gene Market: Industry Opportunities and Strategies to 2028 & 2033 - GlobeNewswire
Oxford BioMedica H1 Loss Narrows, Revenues Climb; Confirms FY24, Medium-term Outlook - RTTNews
Generation of a medicine food homology formula and its likely mechanism in treatment of microvascular angina - Frontiers
Could Q32 Bio’s ‘Skeleton Key’ Open the Door to New Treatments for an Array of Diseases? - University of Colorado Anschutz
Homology Medicines Inc (FIXX) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.07%
大文字化:
|
ボリューム (24 時間):